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Abstract 
During  cardiopulmonary-bypass  matrix-
metalloproteinases released may contribute to
ventricular  dysfunction.  This  study  was  to
determine  plasma  matrix-metalloproteinases
in neonates after cardiopulmonary-bypass and
their  relation  to  post-operative  course.  A
prospective  observational  study  included  18
neonates  having  cardiac  surgery.  Plasma
matrix-metalloproteinases-2  and  9  activities
were  measured  by  gelatin-zymography  pre-
operatively,  on  starting  cardiopulmonary-
bypass,  7-8  min  after  aortic  cross-clamp
release,  and  1h,  4h,  24h,  and  3d  after  car-
diopulmonary-bypass.  Plasma  concentrations
of their tissue inhibitors 1 and 2 were deter-
mined  by  enzyme-linked  immunosorbent
assay. Cardiac function was assessed by serial
echocardiography. Paired t-tests and Wilcoxon
tests were used to assess temporal changes,
and linear correlation with simultaneous clin-
ical  and  cardiac  function  parameters  were
assessed  using  Pearson’s  product-moment
correlation coefficient. Plasma matrix-metal-
loproteinases  activities  and  their  tissue
inhibitor  concentrations  decreased  during
cardiopulmonary-bypass.  Matrix-metallopro-
teinase-2  plasma  activity  increased  progres-
sively  starting  1h  after  cardiopulmonary-
bypass and returned to pre-operative levels at
24h. Matrix-metalloproteinase-9 plasma activ-
ity increased significantly after release of aor-
tic  cross-clamp,  peaked  7-8min  later,  and
returned  to  baseline  at  24h.  Plasma  tissue-
inhibitor 1 and 2 concentrations increased 1h
after  cardiopulmonary-bypass.  Cardiac  func-
tion  improved  from  4h  to  3d  after  surgery
(p<0.05). There was no evidence of signifi-
cant correlations between matrix-metallopro-
teinases or their inhibitors and cardiac func-
tion,  inotrope  scores,  organ  dysfunction
scores, ventilation days, or hospital days. The
temporal profile of plasma matrix-metallopro-
teinases and their inhibitors after cardiopul-
monary-bypass  in  neonates  are  similar  to
adults.  In  neonates,  further  study  should
determine whether circulating matrix-metal-
loproteinases are useful biomarkers of disease
activity  locally  within  the  myocardium,  and
hence of clinical outcomes. 
Introduction
Matrix  metalloproteinases  (MMPs)  are
zinc-dependent  endopeptidases  known  for
their  role  in  tissue  remodeling  through  the
degradation  of  extracellular  matrix  compo-
nents,
1 potentially  contributing  to  capillary
permeability  and  neutrophil  exudation  in
inflammatory  states.
1,2 Matrix  metallopro-
teinases are inhibited by tissue inhibitors of
matrix  metalloproteinases  (TIMPs),  and
imbalances between activation and inhibition
of MMPs may result in uncontrolled proteoly-
sis.  Matrix  metalloproteinases-2  and  9  have
been shown to be involved in the development
of cardiac disease, including congestive heart
failure and myocardial infarction.
3-6In addition
to a role in remodeling of extracellular matrix,
MMP2 and 9 are involved in acute processes
such as the aggregation of platelets
7 and regu-
lation of vascular tone.
8 Recently, MMP2 was
found to be activated and to degrade troponin
I during reperfusion of isolated rat hearts fol-
lowing ischemia, and this activity was associ-
ated with acute left ventricular dysfunction.
9
Myocardial dysfunction attributed to reper-
fusion of transiently ischemic myocardium is
commonly observed after cardiac surgery with
cardiopulmonary bypass (CPB). The activation
of MMPs has been suggested as one possible
mechanism.
10 In isolated rat hearts subjected
to ischemia-reperfusion, MMP2 activity in the
coronary effluent was increased, and correlat-
ed positively with duration of ischemia and
negatively with recovery of mechanical func-
tion after reperfusion; moreover, mechanical
dysfunction  after  ischemia-reperfusion  was
improved by MMP2 antibody and worsened by
semi-purified  MMP2  infusion.
10 Plasma  and
myocardial  MMP2  and  9  activities  in  adults
having CPB for coronary artery bypass grafting
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increase in a specific temporal pattern, 
11-14 and
myocardial  MMP2  and  9  activities  correlate
negatively with ventricular function after sur-
gery.
15
To our knowledge, little is known about the
temporal profile of MMPs and TIMPs in the
plasma  of  neonates  undergoing  cardiac  sur-
gery for congenital heart disease. We therefore
designed this prospective cohort pilot study to
examine  the  temporal  changes  of  plasma
MMP2 and 9 activities and plasma TIMP1 and
2 concentrations in neonates with congenital
heart disease having intracardiac surgery, and
to describe their relationship to post-operative
clinical course and cardiac function.
Design and Methods
Patient population and recruitment
Neonates equal to or less than six weeks of
age who were to undergo surgery with CPB for
congenital heart disease were identified upon
admission to the Neonatal Intensive Care Unit.
Exclusion criteria included: prior CPB or sur-
gery in the previous two weeks; and document-
ed  infection  within  four  days  of  surgery,
defined as a positive blood culture or a clinical
diagnosis of pneumonia, urinary tract infec-
tion or wound infection requiring a course of
antibiotic treatment. The study was approved
by  the  institutional  Health  Research  Ethics
Board and was performed in accordance with
the  ethical  standards  of  the  Helsinki
Declaration. Following signed informed legal
guardian consent, prospective data was collect-
ed.  Demographic  data,  pre-operative  clinical
state,  operative  details,  and  post-operative
course (including the duration of mechanical
ventilation,  hospital  length  of  stay,  inotrope
scores,
16 and  Pediatric  Logistic  Organ
Dysfunction Scores
17) were recorded. 
Blood sample collection
Arterial blood samples (0.5 mL) were col-
lected in glass tubes containing 3.15% sodium
citrate (9:1, v:v) and immediately centrifuged
(3000  g,  10min,  4°C).  The  plasma  fraction
was then removed, frozen in liquid nitrogen,
and  stored  at  –80°C.  Blood  samples  were
obtained from arterial catheters less than 24h
prior  to  surgery  (designated  as  t1).  Intra-
operative samples were collected at the fol-
lowing times: immediately after cannulation
and institution of CPB (baseline, t2), immedi-
ately  after  the  release  of  the  aortic  cross-
clamp (t3), and 7-8min after release of the
aortic cross-clamp (t4). After separation from
CPB, samples were obtained at 1±0.5h (t5),
4±0.5h  (t6),  18-24h  (t7)  and  66-72h  (t8).
Unless  specified  otherwise,  measurements
were collected at each of these time points for
MMPs and TIMPs assays.
Measurement of matrix metalloproteinases-2
and 9 plasma activities
Gelatinolytic activities of plasma MMPs were
examined  by  zymography  as  previously
described.
18 Briefly, samples in sodium dodecyl-
sulphate buffer were subjected to 8% polyacry-
lamide  separating  gels  containing  gelatin  (2
mg/mL,  Sigma).  The  supernatant  of  human
fibrosarcoma  HT1080  cells  (American  Type
Culture  Collection,  Rockville,  MD,  USA)  was
used as a standard for MMPs. Following elec-
trophoresis,  the  gels  were  washed  with  2.5%
Triton X-100 and incubated overnight at 37ºC in
50  mM  Tris-HCl  buffer  (0.15  M  NaCl,  5  mM
CaCl2, 50 mM Tris HCl and 0.05% NaN3, pH 7.6).
Gelatinolytic activities were visualized as trans-
parent bands against a Coomassie Blue stained
background. The gels were scanned and ana-
lyzed  using  SigmaGel  measurement  software
(Jandel  Corporation,  San  Rafael,  CA,  USA).
Matrix metalloproteinase activity was calculated
as per amount of protein and expressed in arbi-
trary units (AU). The plasma protein concentra-
tion  was  assessed  by  bicichoninic  acid  assay
(Sigma)  using  bovine  serum  albumin  as  the
standard.
Quantification of tissue inhibitor of metallo-
proteinase-1 and 2 plasma concentrations
The plasma concentrations of TIMP1 and 2
were  determined  by  commercially  available
enzyme  immunoassays  (Oncogene  Research
Products, Darmstadt, Germany) using specific
human  TIMP1  or  2  antibodies,  respectively.
The  manufacturer’s  instructions  for  sample
preparation and assay were adhered to with
minor  modifications.  The  concentration  of
TIMP1 or 2 was determined by interpolation
from a standard curve. 
Post-operative assessment of cardiac function
The  post-operative  cardiac  function  was
assessed by serial transthoracic echocardiog-
raphy at 4h, day 1-2, and day 5-7 following sur-
gery. Parameters measured included: shorten-
ing fraction, velocity of circumference shorten-
ing, left ventricular outflow tract velocity, and
corrected  maximum  power.  The  echocardio-
graphic examination was performed by one of
the authors (JD) or his delegate and interpret-
ed by JD with no knowledge of the MMP and
TIMP results.
Statistics
Data are expressed in median (mean±stan-
dard  deviation,  range).  Paired  t-tests  and
Wilcoxon signed rank tests were used to assess
percent changes from CPB baseline (immedi-
ately  after  cannulation;  t2).  Percent  change
was only calculated for patients whose base-
line measurement was not zero (100%× [final
-  baseline]/baseline).  For  the  echocardio-
graphic parameters, changes over time were
examined  using  paired  t-tests  adjusted  for
multiple  testing  by  the  Bonferroni  method.
Each of the MMP activities and TIMP concen-
trations were assessed for significant linear
correlation with simultaneous clinical and car-
diac function parameters using the Pearson’s
product-moment  correlation  coefficient  (r)
and associated t-test adjusted for multiple test-
ing by the Bonferroni method. The Statistical
Package for the Social Sciences (SPSS) ver-
sion 11 was used to perform the majority of
analyses.
Results
From February to December 2002, 18 term
neonates  requiring  intracardiac  surgery  for
congenital heart disease were enrolled. There
were 11 male and 7 female infants, whose sur-
gery was performed at the age of 9 [12±10, 3-
38] days and a weight of 3.4 [3.4±0.6, 2.1-4.9]
kilograms. Diagnoses included hypoplastic left
heart syndrome (5), transposition of the great
arteries (5), interrupted aortic arch (2), total
anomalous  pulmonary  venous  drainage  (2),
tetralogy of Fallot (1), truncus arteriosus,(1)
atrial and ventricular septal defects (1), and
ventricular septal defect with hypoplastic aor-
tic arch (1). The intraoperative and post-oper-
ative clinical features are shown in Table 1.
There were no post-operative deaths.
Plasma MMP2 and 9 activities
The gelatinolytic activities of MMP2 and 9 in
the plasma were detected at 72 kDa and 92
kDa, respectively (Figure 1A). Following a dra-
matic decrease immediately after cannulation
for CPB (baseline; t2), the plasma MMP2 activ-
ity increased at 1h after separation from CPB
(p<0.01) and progressively recovered to pre-
operative levels within the first post-operative
24h (Figure 1B). The plasma MMP9 activity
after  cannulation  for  CPB  (baseline;  t2)
decreased significantly, increased immediately
after  the  release  of  aortic  cross-clamp
(p<0.005), and peaked 7-8min later (p<0.005).
The plasma MMP9 activity then progressively
decreased  and  by  24h  post-operatively,  the
plasma  MMP9  activity  was  similar  to  CPB
baseline (Figure 1C). The plasma MMP9 activ-
ity  then  remained  stable  in  the  subsequent
48h.
Plasma TIMP1 and 2 concentrations
The  plasma  TIMP1  and  2  concentrations
decreased after cannulation for CPB (baseline;
t2)  and  increased  at  the  subsequent  times.
The increase in plasma TIMP1 concentration
was significant immediately after the release
of aortic cross-clamp (p<0.05) and at 1h after
separation from CPB (p<0.001) (Figure 2A).
The increase in plasma TIMP2 concentration
was  less  dramatic  immediately  after  theArticle
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release  of  aortic  cross-clamp  (p=0.07),  and
became significant at 1h after separation from
CPB  (p<0.0001)  (Figure  2B).  Both  plasma
TIMP1 and 2 concentrations reached their pre-
operative levels at 1-4h after separation from
CPB,  and  remained  stable  for  the  next  72h
post-operatively.
Echocardiographic findings post-operatively
Forty-three  echocardiographic  examina-
tions  were  performed  in  these  18  patients.
Cardiac function determined by the shortening
fraction, velocity of circumference shortening,
left ventricular outflow tract velocity, and cor-
rected maximum power improved during the
post-operative period. There were statistically
significant  increases  in  these  functional
parameters on post-operative day 1-2 (vs. 4h;
Table 2). No evidence of significant changes
over time were found in the myocardial per-
formance index and Ea (early diastolic filling
phase on tissue doppler). No evidence of fur-
ther significant improvement in the functional
parameters was found on day 5-7 post-opera-
tively (vs. day 1-2, Table 2). 
Plasma matrix metalloproteinase activities
and TIMP concentrations, cardiac function,
and clinical outcomes 
For echocardiographic parameters, correla-
tions with simultaneous or earlier MMP activ-
ity and TIMP concentrations were determined.
There was no evidence of statistically signifi-
cant correlations between plasma MMP activi-
ties or TIMP concentrations and parameters of
post-operative  cardiac  function  including
shortening fraction, velocity of circumference
shortening, left ventricular outflow tract veloc-
ity,  and  corrected  maximum  power.  Among
clinical parameters, no evidence was found of
statistically  significant  correlations  between
the MMP activities and the TIMP concentra-
tions  and:  heart  rate,  mean  blood  pressure,
arterial pH, base deficit, lactate, or inotrope
scores. In addition, the maximum change in
plasma MMP activities and TIMP concentra-
tions  did  not  correlate  with  intraoperative
parameters, the duration of mechanical venti-
lation,  hospital  stay,  inotrope  scores,  or
Pediatric Logistic Organ Dysfunction Scores.
No  evidence  of  significant  correlation  was
found  between  simultaneous  plasma  MMP
activities and TIMP concentrations.
Discussion
We  report  the  temporal  profile  of  plasma
MMP2 and 9 activities and their TIMP concen-
trations  in  18  neonates  undergoing  cardiac
surgery with CPB. Our main findings are: 1)
after initially decreasing on institution of CPB,
MMP2 plasma activity increased progressively
starting at 1h after separation from CPB and
returned  to  pre-operative  levels  at  24h;  2)
MMP9 plasma activity was significantly elevat-
ed after release of aortic cross-clamp, peaked
7-8min later, and returned to baseline at 24h;
and 3) there was no evidence of statistically
significant correlation of MMP2 or 9 plasma
activity, or TIMP1 or 2 plasma concentration
and  clinical  outcomes  including  echocardio-
graphic  cardiac  function,  inotrope  scores,
Pediatric  Logistic  Organ  Dysfunction  Score,
ventilation  days,  or  hospital  length  of  stay.
Although MMP activity and TIMP levels have
been examined in adult patients undergoing
CPB, to our knowledge this is the first report of
the temporal profile in neonates having car-
diac surgery with CPB.
The temporal profile of plasma MMP2 and
9 activities
A consistent finding in adults undergoing
Figure 1. (A) A representative zymogram showing the plasma activities of matrix metal-
loproteinase-2 (72 kDa) and matrix metalloproteinase-9 (92 kDa). S: standard. (B) The
temporal profile of the plasma activity of matrix metalloproteinase-2 and (C) matrix met-
alloproteinase-9 in 18 neonates undergoing cardiac surgery. Mean (*), median, 25
th and
75
th percentiles, and extreme values are shown in the boxplots. AU: arbitrary units.  
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coronary artery bypass grafting is an increase
in MMP9 activity from the CPB baseline after
cross-clamp release,
11-14 with a decrease from
peak value within 6h.
11,14 The changes in plas-
ma MMP2 activity have been more variable.
11-15
Mayers  et  al. found  significant  increases  in
myocardial MMP2, but not plasma MMP2 activ-
ity  on  termination  of  CPB.
12 Conversely,
Watanabe et al.
13 and Joffs et al.
11 found an ini-
tial decrease of plasma MMP2 activity during
CPB,  followed  by  a  progressive  increase  in
activity over the 24h after discontinuation of
CPB. We found temporal changes in plasma
MMP activity in neonates remarkably similar
to  these  findings  in  adults.  Plasma  MMP2
activity  increased  post-operatively  from  CPB
baseline,  returning  to  pre-operative  levels
within 24h. An immediate increase of plasma
MMP9  activity  soon  after  aortic  cross-clamp
release gradually returned to pre-operative lev-
els 4h later. An increase in MMP2 and 9 levels
post-operatively  was  also  found  in  children
(age 4-34 months) by Pasnik et al.
19
There are several possible sources for plas-
ma MMP activity after CPB.
6 Neutrophils and
platelets can release MMPs into plasma upon
activation during exposure to the high oxygen
environment  and  foreign  CPB  surfaces.
12,14,20
However,  Mayers  et  al. found  that  the
increased MMP activity in heart tissue was not
caused by an influx of inflammatory cells, and
instead was associated with diffuse increase
in MMP expression within myocytes.
12 These
findings  suggest  the  source  of  plasma and
myocardial MMPs may be different. 
Table 1. Intraoperative and post-operative clinical features of neonates with cardiac surgery.
a
Intra-operative 4 hours post-operative 3 days post-operative
Heart rate (beats/min) 89 [83±39, 0-143] (n=10) 165 [164±13, 145-192] 149 [148±17, 105-175]
Mean arterial blood pressure (mmHg) 28 [28±7, 11-40] 58 [58±6, 49-69] 62 [63±10, 35-84]
Arterial pH 7.34 [7.37±0.09, 7.27-7.67] 7.43 [7.43±0.06, 7.33-7.55] 7.41 [7.40±0.08, 7.17-7.52]
Lactate (mmol/l) 2.1 [2.1±0.7, 0.7-3.7] 2.6 [3.5±2.5, 0.8-9.5] 1.0 [1.1±0.5, 0.5-2.7]
Aortic cross-clamp time (min) 50 [56±23, 31-123]  --- ---
Deep hypothermic circulatory arrest  (min) 20 [26±24, 0-79] --- ---
Cardiopulmonary bypass time (min) 92 [175±214, 61-990] --- ---
Inotrope score --- 10.5 [14+11, 0-40] 12.5 [13.6±10.7, 0-40]
b
Post-operative ventilation (hours) --- --- 156 [196±165, 26-735]
Hospital stay (days)   --- --- 29 [34±20, 11-76]
aData reported as median [mean±SD, range].  
bData from time 24h post-operatively.  There were 16-18 subjects for each variable. 
Table 2. Post-operative cardiac function by serial echocardiographic examinations in neonates. 
4 hours post-operative 1-2 days post-operative 5-7 days post-operative
Shortening fraction (%) 36 [30±11, 8-46] 40 [39±8, 23-51]
a 44 [44±12, 20-67]
a
Velocity of circumferential fiber shortening (circ/sec) 1.4 [1.3±0.5, 0.3-2.0] 1.7 [1.7±0.5, 0.8-2.4]
a 1.7 [1.7±0.7, 0.8-3.4]
Left ventricular outflow tract velocity (cm/sec) 50 [53±16, 22-92] 60 [69±22, 45-129]
a 68 [80±41, 41-162]
Myocardial performance index 0.62 [0.73±0.36, 0.24-1.50] 0.62 [0.63±0.16, 0.43-0.92] 0.50 [0.56±0.27, 0.35-1.38]
Ea (cm/sec) 58 [65±23, 33-111] 63 [68±20, 46-111] 61 [67±12, 58-91]
Corrected maximum power 2585 [2784±1551, 1148-6020] 3508 [3788±1942, 1623-8450]
a 3195 [3743±2025, 1526-8000]
ap<0.017 vs. 4h post-operative (paired t-test).  Data reported as median [mean±SD, range].  There were 12-15 subjects for each echocardiogram variable.
Figure 2. The temporal profile of the plasma concentrations of (A) tissue inhibitor of
metalloproteinase-1  and  (B)  tissue  inhibitor  of  metalloproteinase-2  in  18  neonates
undergoing cardiac surgery.  Mean (*), median, 25
th and 75
th percentiles and extreme val-
ues are shown in the boxplots.  
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The functional recovery of cardiac function
after cardiopulmonary bypass
To  study  the  cardiac  function  of  complex
heart anatomy in the neonate is difficult.
21 We
serially  measured  several  echocardiographic
parameters of systolic and diastolic functions
of the dominant ventricle. We observed a sig-
nificant  improvement  in  cardiac  function
assessed by shortening fraction, velocity of cir-
cumference  shortening,  left  ventricular  out-
flow  tract  velocity,  and  corrected  maximum
power during the first two days post-operative-
ly, with no further significant increase in the
subsequent  four  days.  This  improvement
occurred with similar inotrope scores (14±11
vs. 13.6±10.7, p=ns). This finding of an early
nadir  in  post-operative  cardiac  function  is
compatible  with  the  reports  of  a  typical
decrease in cardiac index, and increase in sys-
temic vascular resistance and pulmonary vas-
cular resistance in the first 12h, returning to
baseline  by  24h  after  cardiac  surgery  in
neonates.
16
The relationship between plasma matrix
metalloproteinase activity and clinical 
outcomes
Plasma  MMP  activity  theoretically  may
affect post-operative cardiovascular homeosta-
sis through their effects on platelet aggregato-
ry function, vasomotor control, capillary per-
meability, and acute lung injury.
2,7,8,22 In addi-
tion, changes in plasma MMP2 and TIMP2 con-
centrations  may  play  a  role  in  left  ventricle
remodeling after cardiac surgery.
13,23
We did not find evidence of statistically sig-
nificant  correlations  between  MMP  plasma
activity or TIMP concentration and clinical out-
comes including post-operative cardiac func-
tion,  inotrope  and  Pediatric  Logistic  Organ
Dysfunction Scores, ventilation days and hos-
pital stay. There are several potential explana-
tions for this finding. Although most reports in
adults describe changes in plasma MMP activ-
ity referenced to CPB baseline,
11,12 this may be
misleading  in  neonates.  In  neonates  with  a
blood volume of 80 mL/kg, CPB contributes sig-
nificant extracorporeal blood volume (approxi-
mately 500 ml packed red blood cells: saline
mixture), diluting plasma and accounting for
the dramatic decrease in plasma MMP activity
with  initiation  of  CPB.  Nevertheless,  we
believe this dilution effect would be minimal
on the relative plasma MMP activity over time
post-operatively. We did not study myocardial
tissue  MMP  activity  due  to  technical  limita-
tions.  In  children  with  Kawasaki  disease,
peripheral blood levels of MMP2 and 9 were not
significantly  correlated  with  coronary  artery
damage, even though coronary tissue MMP lev-
els in children and animals are associated with
coronary  artery  damage.
24 Lalu  et  al.,  in  15
adults  undergoing  coronary  artery  bypass
grafting surgery with CPB, found significant
negative  correlations  between  left  ventricle
stroke work index at 3 h following reperfusion
and left atrial tissue MMP2 and 9 activities (r=
-0.56 and -0.89, respectively), but no correla-
tion with the plasma MMP activity.
15
Study limitations
This  study  has  limitations  that  affect  the
clinical implications of our findings. The small
sample size, statistical correction for multiple
testing, and heterogeneous types of congenital
heart disease may preclude identifying corre-
lations between some variables. In addition,
our patients had very good outcomes, and this
may have limited our ability to detect associa-
tions between MMP activities, TIMP concen-
trations, and adverse outcomes. Nevertheless,
despite the heterogeneous cardiac lesions, all
the neonates had hemodynamically significant
congenital heart disease, significant exposure
to  CPB  and  aortic  cross-clamp  times,  often
with deep hypothermic circulatory arrest, often
had  tachycardia  and  high  lactate  early  post-
operatively, and significant need for post-oper-
ative inotropes and ventilation days (Table 1).
In addition, these patients did have a signifi-
cant nadir in cardiac function early post-oper-
atively (Table 2). As mentioned above, we did
not measure myocardial tissue MMP activity,
which may better reflect the myocardial envi-
ronment. Given these significant limitations,
our results, particularly regarding the lack of
association of MMP activities and TIMP con-
centrations with clinical outcomes, should be
interpreted with caution. 
We chose to measure MMP activity, and not
concentration, similar to adult studies.
11-15 It is
possible  that  total  MMP  concentrations  may
have  given  different  results.  However,  we
believe that it is the activity of the mediators
that is important, and not the total level which
may  include  potentially  inactive  mediators.
Furthermore, in the only pediatric study that
examined MMP2 and 9 levels after CPB (in 28
children aged a mean 11.3 months, range 4-34
months),  the  concentrations  were  generally
similar in temporal profile to what we found
for activity levels in neonates.
19
Conclusions
Our  findings  can  be  considered  the  first
pilot study of MMPs in neonates after cardiac
surgery,  and  should  inform  the  design  of
future investigations. In neonates after intrac-
ardiac surgery, we describe temporal profiles
of MMP2 and 9 activities, and TIMP1 and 2
concentrations in plasma that were similar to
those found in adults after CPB. We did not
find evidence of a statistically significant asso-
ciation  of  circulating  levels  of  MMPs  and
TIMPs with clinical outcomes, and suggest that
it is unclear if circulating levels are useful bio-
markers of the local myocardial tissue environ-
ment.  Therefore,  the  relationship  between
plasma and myocardial MMP activity in infants
should be determined. Given our study limita-
tions, whether there is a lack of association
between circulating levels of MMPs and TIMPs
with clinical outcomes in neonates after car-
diac  surgery  should  be  confirmed  by  future
study.  This  has  important  implications  for
future therapeutic intervention.
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